Randomised phase II study of sequentially high dose Methotrexate and Fluorouracil combined with Epirubicin (FEMTX) versus FEMTX plus Cisplatin (FEMTX-P) in advanced gastric cancer
Not Applicable
Completed
- Conditions
- Oesophagus, Stomach CancerCancerMalignant neopplasm of other or ill-defined digestive organs
- Registration Number
- ISRCTN69546136
- Lead Sponsor
- Pharmacia Ltd & Upjohn (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Aged less than 70 years
2. Histologically confirmed locally advanced and/or metastatic gastric cancer
3. Measurable or evaluable disease
4. Karnofsky status 80-100
5. Adequate renal, hepatic and bone marrow function
Exclusion Criteria
1. Previous chemotherapy or radiotherapy
2. Pleural or peritoneal effusions which cannot be adequately drained
3. Central Nervous System (CNS) metastases
4. History of previous or concomitant malignancy except squamous or basal cell carcinoma of the skin which has been effectively treated and carcinoma in situ of the cervix which has been treated operatively only
5. Other medical contraindications to treatment protocols
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration